Cystic Fibrosis (CF) Therapeutics Market Report 2025

The cystic fibrosis (CF) therapeutics market size has grown rapidly in recent years. It will grow from $7.54 billion in 2024 to $8.31 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to advancements in targeted therapies, growing understanding of CF genetics, patient advocacy and awareness, government support for research, orphan drug designations, incentives for rare disease research.

The cystic fibrosis (CF) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rise in C patient population, regulatory approvals for novel therapies, focus on personalized medicine, increasing investment in biomarker research, expanded newborn screening programs, healthcare policy support. Major trends in the forecast period include expansion of CFTR modulators, gene editing technologies, early intervention strategies, improved diagnostic techniques, telehealth and remote monitoring, healthcare digitalization, chronic disease management.

The projected increase in the population affected by cystic fibrosis (CF) is set to be a driving force behind the expansion of the cystic fibrosis therapeutics market. CF, an inherited condition impacting the lungs, digestive system, and other organs, necessitates therapeutic interventions to thin lung mucus, making it easier to expel. As the number of individuals suffering from cystic fibrosis rises, the demand for effective CF therapeutics is expected to soar. An illustrative example is a report released by The Cystic Fibrosis (CF) Foundation in July 2022, revealing a surge in CF cases, with almost 40,000 affected individuals in the United States and over 105,000 diagnosed worldwide. This escalation in CF patients is a significant driving factor fueling the cystic fibrosis therapeutics market growth.

The burgeoning emphasis on personalized medicine and targeted therapies is poised to drive the cystic fibrosis therapeutics market forward. Personalized medicine involves tailoring medical care based on patients' unique genetic makeup, proteins, and other biological factors, enabling precise and individualized treatments. This approach aids in comprehending the intricate genetic mutations underlying CF, paving the way for customized treatment plans aligned with each patient's distinct genetic profile. Notably, The Scope and Significance of Progress in 2022 report by the Personalized Medicine Coalition highlighted the US Food and Drug Administration's approval of 12 personalized medicines in 2022, constituting approximately 34% of all newly approved therapeutic molecular entities. This growing focus on personalized medicine and targeted therapies is a driving force behind the expansion of the cystic fibrosis therapeutics market.

Leading companies in the cystic fibrosis (CF) therapeutics market are developing innovative treatment and patient care solutions, such as the cystic fibrosis innovation hub network, to speed up research, enhance treatment options, and foster collaboration in the creation of new therapies for CF patients. The cystic fibrosis innovation hub network serves as a collaborative platform or initiative aimed at expediting the research and development of new treatments for cystic fibrosis (CF). For example, in October 2024, LifeArc, a UK-based charity and life sciences organization focused on translating scientific research into effective healthcare solutions, launched the UK’s first Cystic Fibrosis Innovation Hub Network. This hub is designed to advance research and development for cystic fibrosis (CF) treatments, promoting collaboration among healthcare providers, researchers, and patients. Initiated as part of a larger effort to accelerate innovation in cystic fibrosis therapies, the hub concentrates on discovering new pathways for drug development and enhancing patient outcomes.

Key players within the cystic fibrosis (CF) therapeutics market are actively directing their efforts towards strategic investments aimed at expanding their presence and fortifying their market positions. Strategic investment in medical research encompasses a deliberate allocation of resources, expertise, and funding into scientific research endeavors with the primary objectives of advancing medical understanding, developing innovative treatments, and refining healthcare protocols. An exemplary instance of such strategic investment occurred in January 2023 when the Cystic Fibrosis Foundation (CF Foundation), a US-based non-profit organization dedicated to supporting diverse research initiatives for CF cure, announced a significant investment of up to $15 million in ReCode Therapeutics. ReCode, a US-based clinical-stage genetic medicines and biotechnology company, specializes in employing advanced delivery mechanisms to drive the next wave of messenger ribonucleic acid (mRNA) and gene correction therapeutics. This substantial investment is intended to facilitate the development of ReCode's inhaled mRNA-based therapeutic tailored for individuals with cystic fibrosis (CF), particularly those with genotypes unresponsive to approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

In July 2024, Sionna Therapeutics, a US-based healthcare organization, acquired the rights to develop and commercialize several cystic fibrosis (CF) compounds from AbbVie Inc. for an undisclosed amount. This acquisition allows Sionna to focus on the commercialization of three specific compounds: ABBV-2222, ABBV-3067, and ABBV-2851, aimed at enhancing the efficiency of cystic fibrosis (CF) treatment. AbbVie Inc. is a US-based company specializing in cystic fibrosis (CF) therapeutics.

Major companies operating in the cystic fibrosis (CF) therapeutics market include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Pharmaxis, Bayer AG, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals, Translate Bio Inc, Zambon S.p.A.

North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cystic fibrosis (cf) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cystic fibrosis (CF) therapeutics encompasses medications designed to thin and facilitate the coughing up of lung mucus in individuals with this inherited disorder. CF causes severe damage to the lungs, digestive system, and other organs.

The primary drug classes for CF therapeutics include pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Pancreatic enzyme supplements contain pancreatin or pancrelipase, a combination of lipase, amylase, and protease, produced by the pancreas. These supplements can be administered orally or through inhalation. The treatment methods for cystic fibrosis involve a combination of medications and devices to manage the condition effectively.

The cystic fibrosis therapeutics market research report is one of a series of new reports that provides cystic fibrosis therapeutics market statistics, including cystic fibrosis therapeutics industry global market size, regional shares, competitors with a cystic fibrosis therapeutics market share, detailed cystic fibrosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis therapeutics industry. This cystic fibrosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cystic fibrosis (CF) therapeutics market includes revenues earned by entities by providing services that include administration of mucus thinner, airway clearance, and antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.